Advertisement

Topics

Search Results for "Sunitinib"

02:43 EST 9th February 2016 | BioPortfolio

Matching Channels

None

Matching News

[News] Benefits of pazopanib over sunitinib for renal cell carcinoma

A post-hoc analysis of the findings of a randomised, open-label, phase 3 trial of two angiogenesis inhibitors for metastatic renal cell carcinoma has confirmed the overall clinical advantage of pazopa...

Sorafenib, sunitinib may pose cardiovascular risk

(HealthDay)—Older kidney cancer patients treated with sorafenib or sunitinib may face an increased risk of cardiovascular adverse events, according to a study published online Oct. 6 in Cancer.

[Articles] Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

In patients with metastatic non-clear cell renal cell carcinoma, sunitinib improved progression-free survival compared with everolimus. Future trials of novel agents should account for heterogeneity i...

Kidney cancer: Sunitinib: 2/1 is superior to 4/2

Kidney cancer: Trebananib plus sunitinib improves survival outcomes

miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma

Matching PubMed Articles

Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib.

Patients have responded well to the multi-targeted tyrosine kinase inhibitor (TKI) Sunitinib in the clinic. But the severe toxic side effects associated with Sunitinib limit its therapeutic index. To ...

Sunitinib - ibuprofen drug interaction affects the pharmacokinetics and tissue distribution of sunitinib to brain, liver and kidney in male and female mice differently.

Tyrosine kinase inhibitor sunitinib (used in GIST, advanced RCC and pancreatic neuroendocrine tumors) undergoes CYP3A4 metabolism and is an ABCB1B and ABCG2 efflux transporters substrate. We assessed ...

Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.

Vascular endothelial growth factor (VEGF) and mammalian target of rapamycin are well-known therapeutic targets for renal cell carcinoma (RCC). Sunitinib is an agent that targets VEGF receptors and is ...

Sunitinib Induced Immune Thrombocytopenia.

Sunitinib is an oral tyrosine kinase inhibitor which prevents tumor growth and metastatic progression. It was approved for treatment of advanced renal cell cancer, gastrointestinal stromal tumor and a...

Sunitinib suppresses migration of ovarian cancer cells through negative modulation of TGF-β-mediated epithelial-mesenchymal transition.

Objective:To investigate the effect of sunitinib on the migration of ovarian cells and its mechanism of the negative regulation TGF-β mediated of epithelial-mesenchymal transition(EMT) by sunitinib t...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement